Allergan successfully completes $2.9bn LifeCell acquisition

pharmafile | February 2, 2017 | News story | Business Services, Sales and Marketing Allergan, LifeCell 

The acquisition of regenerative medicine firm LifeCell by Allergan for $2.9 billion announced back in December has been completely successfully, the company has announced.

The deal assimilates LifeCell’s portfolio of dermal matrix products into Allergan’s own lineup of medical aesthetic and plastic surgery products such as breast implants and tissue expanders. Among LifeCell’s offerings are human allograft tissue matrix Alloderm, single use high-volume fat grafting device Revolve and industry-standard hernia repair tissue matrix Strattice.

Allergan Chairman and CEO Brent Saunders said of the deal’s closure: “The completion of the LifeCell acquisition is an important milestone for Allergan, serving as our entry point into regenerative medicine as we continue to add to our world-class aesthetic and plastic surgery business. The combination of LifeCell’s novel regenerative medicine products coupled with Allergan’s innovative medical aesthetics and plastic surgery portfolio creates a more complete product offering for plastic surgeons globally.”

The deal was the company’s twelfth last year and is estimated to add around $450 million to its revenues. Allergan will include LifeCell in its upcoming fourth quarter and full year 2016 earnings report on 8 February.

Matt Fellows

Related Content


FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …


$63bn Allergan/AbbVie merger review could be delayed by coronavirus

The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …


Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine

New Phase 3 data has been released showing that both 50mg and 100mg doses of …

Latest content